menu
    • menu
    [{"orgOrder":0,"company":"Secarna Pharma","sponsor":"Lipigon ","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"Antisense oligonucleotide therapies","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Secarna Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Secarna Pharma \/ Lipigon ","highestDevelopmentStatusID":"1","companyTruncated":"Secarna Pharma \/ Lipigon "},{"orgOrder":0,"company":"Secarna Pharma","sponsor":"Sun Yat-sen University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Antisense oligonucleotides","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Secarna Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Secarna Pharma \/ Sun Yat-sen University","highestDevelopmentStatusID":"2","companyTruncated":"Secarna Pharma \/ Sun Yat-sen University"},{"orgOrder":0,"company":"Secarna Pharma","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"Antisense oligonucleotide therapy","moa":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Secarna Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Secarna Pharma \/ Evotec","highestDevelopmentStatusID":"3","companyTruncated":"Secarna Pharma \/ Evotec"},{"orgOrder":0,"company":"Secarna Pharma","sponsor":"Denali Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Partnership","leadProduct":"Antisense Oligonucleotides","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Secarna Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Secarna Pharma \/ Secarna","highestDevelopmentStatusID":"3","companyTruncated":"Secarna Pharma \/ Secarna"},{"orgOrder":0,"company":"Secarna Pharma","sponsor":"Achilles Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Antisense Oligonucleotide","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Secarna Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Secarna Pharma \/ Achilles Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Secarna Pharma \/ Achilles Therapeutics"},{"orgOrder":0,"company":"Secarna Pharma","sponsor":"SciNeuro Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Antisense Oligonucleotide","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"Secarna Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Secarna Pharma \/ SciNeuro Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Secarna Pharma \/ SciNeuro Pharmaceuticals"},{"orgOrder":0,"company":"Secarna Pharma","sponsor":"Celanese","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Secarna Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Sustained-Release Implant","sponsorNew":"Secarna Pharma \/ Secarna Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Secarna Pharma \/ Secarna Pharma"},{"orgOrder":0,"company":"Secarna Pharma","sponsor":"Orbit Discovery","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Antisense Oligonucleotide-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Secarna Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Secarna Pharma \/ Orbit Discovery","highestDevelopmentStatusID":"3","companyTruncated":"Secarna Pharma \/ Orbit Discovery"}]

    Find Clinical Drug Pipeline Developments & Deals by Secarna Pharma

    Menu

    Secarna Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Secarna Pharma

                            Germany arrow
                            Fi Europe 2024
                            Not Confirmed

                            Secarna Pharma

                            Germany arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antisense Oligonucleotide-based Therapy

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Orbit Discovery

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Secarna and Orbit Discovery Collaborate on Targeted Antisense Oligonucleotide Therapeutics

                            Details : The collaboration aims to discover and develop peptide-conjugated targeted antisense oligonucleotide (ASO) therapeutics, potentially offering new treatment options for a wider range of diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 28, 2024

                            Lead Product(s) : Antisense Oligonucleotide-based Therapy

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Orbit Discovery

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Secarna Pharma

                            Germany arrow
                            Fi Europe 2024
                            Not Confirmed

                            Secarna Pharma

                            Germany arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Preclinical

                            Recipient : Celanese

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Celanese and Secarna Collaborate on RNA Research for Antisense Therapies

                            Details : The collaboration aims to develop long-acting antisense oligonucleotide implants using Celanese’s VitalDose® drug delivery platform.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 20, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Preclinical

                            Recipient : Celanese

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Secarna Pharma

                            Germany arrow
                            Fi Europe 2024
                            Not Confirmed

                            Secarna Pharma

                            Germany arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antisense Oligonucleotide

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Sponsor : SciNeuro Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Secarna Pharmaceuticals and SciNeuro Pharmaceuticals Enter into Research and Option Agreement in the Field of ...

                            Details : Under the collaboration, the companies will work together to generate novel Antisense Oligonucleotide therapies directed at targets that play a critical role in diseases of the Central Nervous System.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 27, 2023

                            Lead Product(s) : Antisense Oligonucleotide

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Sponsor : SciNeuro Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Secarna Pharma

                            Germany arrow
                            Fi Europe 2024
                            Not Confirmed

                            Secarna Pharma

                            Germany arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antisense Oligonucleotide

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Achilles Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Secarna Pharmaceuticals and Achilles Therapeutics Sign Research, Option and License Agreement to Develop Optim...

                            Details : Secarna will employ its commercially validated discovery and development platform, LNAplus™, to generate ASO candidates against selected targets that potentially play a central role in the ex vivo optimization of personalized T cell therapies being dev...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 10, 2021

                            Lead Product(s) : Antisense Oligonucleotide

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Achilles Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Secarna Pharma

                            Germany arrow
                            Fi Europe 2024
                            Not Confirmed

                            Secarna Pharma

                            Germany arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antisense Oligonucleotides

                            Therapeutic Area : Neurology

                            Study Phase : Discovery Platform

                            Recipient : Denali Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Secarna Pharmaceuticals and Denali Therapeutics Expand Strategic Partnership for the Discovery and Development...

                            Details : As part of the collaboration, Secarna will employ its commercially validated discovery and development platform, LNAplus™ to generate antisense oligonucleotide candidates against targets relevant for the treatment of neurodegenerative diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 26, 2021

                            Lead Product(s) : Antisense Oligonucleotides

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery Platform

                            Recipient : Denali Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Secarna Pharma

                            Germany arrow
                            Fi Europe 2024
                            Not Confirmed

                            Secarna Pharma

                            Germany arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antisense oligonucleotide therapy

                            Therapeutic Area : Immunology

                            Study Phase : Discovery Platform

                            Sponsor : Evotec

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Secarna, Evotec Form Strategic Antisense Alliance

                            Details : Partnership creates an opportunity for biotech and pharmaceutical companies to enter the growing field of antisense therapeutics by partnering with Evotec and Secarna and to gain access to the companies' co-owned pipeline through a variety of individual ...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 05, 2020

                            Lead Product(s) : Antisense oligonucleotide therapy

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery Platform

                            Sponsor : Evotec

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Secarna Pharma

                            Germany arrow
                            Fi Europe 2024
                            Not Confirmed

                            Secarna Pharma

                            Germany arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antisense Oligonucleotides

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery

                            Sponsor : Sun Yat-sen University

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Secarna Pharmaceuticals Enters into Cooperation with Guangzhou’s Sun Yat-sen University to Develop a Treatme...

                            Details : Under this agreement, Secarna will employ its proprietary LNAplusTM platform to develop antisense oligonucleotides (ASOs) which specifically suppress the expression of a certain host factor that is essential for the viral infection cycle.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 28, 2020

                            Lead Product(s) : Antisense Oligonucleotides

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery

                            Sponsor : Sun Yat-sen University

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Secarna Pharma

                            Germany arrow
                            Fi Europe 2024
                            Not Confirmed

                            Secarna Pharma

                            Germany arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antisense oligonucleotide therapies

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Undisclosed

                            Sponsor : Lipigon

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lipigon Pharma buys LNAplus based antisense drug candidates from Secarna Pharma

                            Details : Under this agreement, Lipigon acquires certain antisense drug candidates, which were developed with Secarna's proprietary LNAplusTM platform, including the corresponding patent portfolio.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 23, 2020

                            Lead Product(s) : Antisense oligonucleotide therapies

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Lipigon

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth